1. Academic Validation
  2. Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats

Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats

  • Biopharm Drug Dispos. 2004 Mar;25(2):69-75. doi: 10.1002/bdd.385.
Venkatesh Atul Bhattaram 1 Jyoti K Paliwal Ram C Gupta
Affiliations

Affiliation

  • 1 Department of Pharmacokinetics and Metabolism, Central Drug Research Institute, Lucknow 226001, India.
Abstract

The pharmacokinetics of centpropazine (CNPZ), an antidepressant, was studied in rats. CNPZ was administered to groups of rats (n=3 to 5) via oral (40 mg/kg), intravenous (5 mg/kg), intraperitoneal (5 mg/kg) and intraduodenal (4 and 8 mg/kg) routes. The AUCs of CNPZ were estimated and the bioavailabilities were calculated. CNPZ was characterized by a short elimination half-life (39.5 min), a high clearance (118 ml/min/kg) and a relatively large volume of distribution (1945 ml/kg) after intravenous administration. After oral administration CNPZ exhibited a very low oral bioavailability ( approximately 0.2%). The total first pass effect (Egit+liver) was calculated as 98.7%. The bioavailability of CNPZ was similar when administered by intraduodenal and oral routes. CNPZ readily penetrated into the brain and reached Cmax by 30 min post oral dosing. About 92.0%+/-0.8% of the drug was bound to serum proteins. Low oral bioavailability of CNPZ following oral administration is likely due to its metabolism by intestinal mucosa and liver.

Figures
Products